Iron Deficiency Anemia Therapy
Mostrando 1-11 de 11 artigos, teses e dissertações.
-
1. Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
ABSTRACT Introduction: The incidence of grade 3-4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to evaluate the incidence of anemia after at least two ye
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019
-
2. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the factors associated with resistance to recombinant human eryth
Braz J Med Biol Res. Publicado em: 07/05/2018
-
3. Iron deficiency in cancer patients
ABSTRACT Anemia is a frequent complication in cancer patients, both at diagnosis and during treatment, with a multifactorial etiology in most cases. Iron deficiency is among the most common causes of anemia in this setting and can develop in nearly half of patients with solid tumors and hematologic malignancies. Surprisingly, this fact is usually neglected b
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-12
-
4. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis
OBJECTIVES: Anemia is a common complication among chronic kidney disease patients on hemodialysis, occurring mostly due to erythropoietin deficiency. This randomized noninferiority trial sought to compare the efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos, a biologics manufacturer affiliated with the Brazilian government, with
Clinics. Publicado em: 2014-08
-
5. Universal iron fortification of foods: the view of a hematologist
With the objective of reducing the high incidence of iron deficiency anemia, the Brazilian National Health Surveillance Agency (ANVISA) adopted Resolution 344 in December 2002, which made the addition of iron and folic acid to all industrialized wheat and maize flours in Brazil compulsory. After a series of doubts about this universal measure of food fortifi
Rev. Bras. Hematol. Hemoter.. Publicado em: 2012
-
6. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia
BACKGROUND: Iron deficiency is the most common disorder in the world, affecting approximately 25% of the world`s population and the most common cause of anemia. OBJECTIVE: To evaluate the efficacy and safety of intravenous iron sucrose (IS) in the treatment of adults with iron deficiency anemia METHODS: Eighty-six adult patients with iron deficiency anemia,
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
7. Intravenous iron therapy: how far have we come?
Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia (IDA) because of its effectiveness and low cost. But unfortunately in many iron deficient conditions, oral iron is a less than the ideal treatment mainly because of adverse events related to the gastrointestinal tract as well as the long course required to treat
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
8. AdesÃo e efeitos colaterais ao uso do sulfato ferroso em diferentes posologias, em mulheres em idade reprodutiva: um ensaio populacional / Adhesion and side effects to the use of ferrous sulfate in different posologies, in reproductive age women: a population trial
O sulfato ferroso (SF) representa o tratamento de eleiÃÃo para um dos problemas de maior magnitude e importÃncia em saÃde pÃblica do mundo, a deficiÃncia de ferro e a anemia ferropriva. No entanto, a baixa adesÃo ao tratamento devido aos efeitos colaterais deste mineral limitando sua efetividade, representa um grande desafio ainda a ser superado no co
Publicado em: 2008
-
9. Abnormal erythrocyte membrane protein pattern in severe megaloblastic anemia.
The erythrocyte membrane protein pattern of patients with megaloblastic anemia was determined by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. In severe megaloblastic anemia, secondary either to folic acid or vitamin B12 deficiency, the erythrocyte membrane protein pattern was grossly abnormal, lacking bands 1, 2 (spectrin), and 3 and having
-
10. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction.
Work performance on a treadmill has been evaluated in normal and iron-deficient rats. Anemia was removed as a variable by adjusting the hemoglobin of all animals to the same concentration. At a hemoglobin compatible with normal work performance, iron-deficient animals showed a marked impairment of running ability as compared to control animals. Iron therapy
-
11. Production of Erythrocytes that Contain Fetal Hemoglobin in Anemia: TRANSIENT IN VIVO CHANGES
Serial microscopic immunodiffusion assays of F cells, i.e., erythrocytes that contain fetal hemoglobin (HbF), in four individuals recovering from anemia demonstrate initial increases in the percentage of circulating reticulocytes that contain HbF (F reticulocytes) and subsequent increases in the percentage of mature erythrocytes that contain HbF (F erythrocy